Category Archives: Industry: Healthcare

Healthcare is an ever evolving industry, and field. These Press Releases, will keep you up to date on the newest, greatest, best, solutions available.

Inspirus Places Top 5 in the Baker’s Dozen Customer Satisfaction Ratings

[ad_1]

Inspirus, a Sodexo Group company and leader in elevating employee experiences and optimizing organizational culture through recognition and reward solutions, has been recognized once again on the HRO Today Baker’s Dozen Customer Satisfaction Ratings: Recognition list.

In this latest achievement, Inspirus has been ranked 5th for Overall Customer Satisfaction in Recognition and Quality of Service on the HRO Today Baker’s Dozen list. The HRO Today Baker’s Dozen Customer Satisfaction Ratings are calculated solely on customer feedback. Through an online survey, verified respondents answered questions about the quality of service, deal size, and breadth of service received from their recognition provider. HRO Today aggregates this data using a predetermined algorithm. Questions and categories are weighed based on importance, with special emphasis given to questions pertaining to the quality of customer service. These weights determine the final published rankings. Inspirus, where employees champion the idea “Bring Joy to Work, One Experience at a Time,” has made the prestigious list for 13 consecutive years.

“It is an honor to be included on this prestigious list once again and we remain committed to connecting all employees through meaningful recognition,” says CEO at Inspirus and Sodexo Benefits and Rewards Services, USA, Tatiana Frierson. “This has been a challenging year for many organizations, and I am so proud of our people for ensuring our solutions and services continue to meet the needs and expectations of our clients.”

“For more than a decade, Inspirus has been ranked by our clients as a top provider on the HRO Today Baker’s Dozen Customer Satisfaction Ratings list,” says Inspirus Senior Vice President of Customer Experience, Theresa Harkins-Schulz. “We would like to thank our clients for continuing to recognize us as a top provider and for their partnership. Also, many thanks to the Inspirus team for always striving to create a great customer experience and leading with a servant’s heart.”

Inspirus strives to provide innovative solutions that help clients engage their employees. We continue to listen to our clients’ needs and feedback through our annual Client Experience Survey. In 2020, Inspirus ranked highly with an overall 95% satisfaction rating receiving the highest marks in areas of customer service and client satisfaction.

Key results from the Inspirus 2020 Client Experience Survey include:

  • Overall Satisfaction with Inspirus Account Team 95%
  • Ease of Working with Inspirus 95%
  • Responsiveness 95%
  • Overall Satisfaction with Partnership 96%

Inspirus provides solutions and services that foster connections and a sense of belonging for everyone.

About Inspirus

Inspirus believes employees make up the foundation of culture, shaped and evolved through every day experiences that are essential to the development of strong, high-performing organizations. Through our technology and integrated solutions, we elevate the employee experience and optimize organizational culture by providing a holistic approach to the entire employee journey. We seek to influence the employee experience through our six Quality of Life dimensions: recognition, health and well-being, personal growth, physical environment, social interaction, and ease and efficiency.

Only Inspirus combines an integrated rewards engine, communication tools, and analytics into a single platform spanning recognition, service anniversary, well-being, and diversity and inclusion. Through Sodexo’s broader mission of improving the Quality of Life of all we serve, Inspirus aims to bring joy to work, one experience at a time.

Visit inspirus.com for more information.

Share article on social media or email:

[ad_2]

NeoTract Designates Dr. Keith Xavier as UroLift® Center of Excellence

[ad_1]

News Image

“This designation recognizes Dr. Keith Xavier as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Keith Xavier, M.D., Urology Partners of North Texas in Arlington, TX, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Xavier has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Keith Xavier as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

[ad_2]

Dr. Robert A. Kayal’s Team of NJ Top Docs at Kayal Orthopaedic Center, PC Continues To Grow

[ad_1]

Dr. Robert Kayal

Dr. Robert Kayal

The list of reviewed and approved NJ Top Docs at Kayal Orthopaedic Center, PC is continuously growing. Kayal Orthopaedic Center is home to an elite team of surgeons who are fully committed to skillful, restorative patient care.

Patients in Franklin Lakes, Glen Rock, Westwood, Paramus, Paterson, Garfield, North Bergen, Union City and Wyckoff, New Jersey, as well as in Stony Point, New York choose Kayal Orthopaedic Center for its expertise and compassionate care.

Robert A. Kayal, MD is the founder, president and CEO of Kayal Orthopaedic Center, PC.

This year marks Dr. Kayal’s tenth consecutive year being reviewed and approved by NJ Top Docs. Dr. Robert A. Kayal is a regional pioneer of customized knee and partial & patellofemoral knee replacement technology.

The following providers at Kayal Orthopaedic Center, PC have also been reviewed and approved by NJ Top Docs for 2020. They have been organized by specialty.

Orthopedic Surgery

  • Dr. Aaron Greenberg
  • Dr. Paul Kovatis
  • Dr. Ernest Pope
  • Dr. Amit Sood


Pain Management


Podiatry

  • Dr. Chad Rappaport
  • Dr. Theresa Ronna


Rheumatology

  • Dr. Irina Raklyar
  • Dr. Alan Zalkowitz


The Kayal Orthopaedic Center team is committed to building patient relationships and helping you get the most out of life.

All of the above NJ Top Docs are committed to delivering compassionate, quality care to each patient that walks through their doors. Each physician is the best in their field—delivering the finest in orthopedic treatment, sports medicine expertise and musculoskeletal disease management.

To learn more about Kayal Orthopaedic Center and how they can help improve your life, please click here: https://njtopdocs.com/nj-doctors/drkayal/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



[ad_2]

Knipper’s New ‘Samplicity’ Platform Redefines Sample Management Market

[ad_1]

Named for its simple approach to sample management, Samplicity is an exclusive suite of technology, services, and support, and is the only completely self-contained, sample management platform available.

Samplicity’s fully integrated platform brings to the market a rapid deployment model, coupled with flexible configuration technology to address virtually every sampling need. Agile and modular, its scalable components are well-suited for the small to mid-size company, up to and including large enterprise organizations. Knipper has utilized its deep knowledge of the market in developing this revolutionary approach to sample management. Coupled with Knipper’s one point-of-contact approach, clients enjoy an efficient, scalable, and cost-effective solution to meet all their sampling needs. Hailed as the only end-to-end sample management provider in the market, this new integrated technology is the next milestone in a long history of innovation in the samples market. “The platform brings forth a new single source of practitioner information regardless of marketing channel. In addition, this level of seamless integration avoids traditional pitfalls of contradicting data from multiple sources, conflicting business rules, mismanaged allocations, and the need for multiple suppliers,” states Knipper’s Senior Vice President of Commercial Development and Integration, Eric Johnson.

“Samplicity is sampling, simplified and without compromise,” states Knipper CEO Michael Laferrera. “Thanks to the efforts of an unsurpassed team of in-house professionals, we’ve developed a total support and service solution to surpass the current and future needs of clients, practitioners, and patients.”

Supported by a full complement of fulfillment, distribution, and logistics capabilities, Samplicity’s core service areas include:

  • An E-sampling portal for practitioners to request product samples, patient support materials, and product literature that can be deployed as a single or multitenant platform.
  • An intuitive business rule-based sales representative portal for the ordering of samples and product literature.
  • A built-in rock-solid sample, accountability module for ensuring compliance with PDMA guidelines.
  • A robust business rule and order processing engine that guarantees timely, accurate and compliant distribution.
  • Integration with Knipper’s Contact Center, which performs practitioner and sales rep outreach.
  • A dynamic enterprise reporting suite providing access to all sample related data in an easy-to-use interface.
  • An integrated patient portal through which consumers can order OTC medications direct from the manufacturer.

The platform helps clients achieve goals more economically and with fewer resources. Sales personnel can spend their time selling rather than managing their sample orders, or the sample requests of their customers. Marketing directors’ benefit from Samplicity’s intuitive dashboard to expand sample programs effectively and cost efficiently. Finally, emerging companies can take advantage of Samplicity’s multiple functions to avoid managing multiple suppliers and subsequently reduce costs.

Anticipation for Samplicity is due in part to Knipper’s stellar reputation, which spans more than three decades. More than 100 well-known life science organizations rely on Knipper’s programs and services. As a responsive and trusted resource, Knipper frequently supports the entire product lifecycle from     pre-launch consultation to end of patent. This long-term success is attributed to the experienced Knipper team, who approaches every project with a “one contact, one team, one resource” client-centric perspective.

“The singular focus and ultimate goal of Samplicity is to enable organizations to place the most advanced pharmaceutical products in the hands of patients who benefit from them the most. This supports our corporate vision of creating the shortest path between patient and therapy,” notes Laferrera.

# # # #

About Knipper and Company, Inc.

Knipper and Company, Inc., a leading supplier of end-to-end pharmaceutical sample management services in the U.S., has been purpose-built on a strong foundation of more than 30 years of healthcare service, support, and excellence. The company has locations throughout New Jersey and Indiana. For more information on Knipper and Company, please visit http://www.knipper.com.

About Samplicity

Samplicity is the only fully integrated product sample management platform in existence, with seven different product and service areas to meet a full-range of sampling needs. Knipper works closely with clients to identify strategic goals and objectives, and tailors Samplicity to meet those needs. Among these specialized offerings are: Sample Order Processing, Sample Accountability, Sample Send, Direct to Representative Sample Fulfillment, Representative to Practitioner Ordering, Direct to Practitioner Sampling, E-sampling, and OTC Commercialization. For more information, please visit http://www.knipper.com/samplicity.

For additional press information, please contact:

Ilena Della Ventura

Delia Associates

T. 908-534-9044

E. Idellaventura@delianet.com

Share article on social media or email:

[ad_2]

Cimcor Provides Zoom with Security and Compliance Technology

[ad_1]

CimTrak Logo

The need for real-time security and compliance has continued to scale up as the use of Zoom increases globally. Working with Cimcor and implementing CimTrak ensures our teams are able to comply with expanding security and regulatory requirements, while being able to mitigate risks in real-time.

Cimcor announced that Zoom Video Communications, Inc. has turned to the CimTrak Integrity Suite File and System Integrity Monitoring software to support evolving business needs, innovations, and continued growth as millions of users globally utilize Zoom. Cimcor and the award-winning CimTrak Integrity Suite have committed to delivering to Zoom a security, integrity and compliance solution enterprise-wide. Zoom first began utilizing the CimTrak software in 2019, to achieve compliance for Service Organization Controls (SOC) 2 Framework and FedRAMP compliance requirements.

Richard Farley, Deputy CISO at Zoom said, “The need for real-time security and compliance has continued to scale up as the use of Zoom increases globally. Working with Cimcor and implementing CimTrak ensures our teams are able to comply with expanding security and regulatory requirements, while being able to mitigate risks in real-time.”

Meeting the extensive increase and rapid demand for users and services, Zoom had a need for additional integrity monitoring and security for the millions of participants using the video meeting platform. Requiring increased coverage and security for servers and networks devices, Zoom selected the CimTrak Integrity Suite for its advantages in integrity, reliability, scalability, and performance for both on-premise and cloud environments. CimTrak’s next-generation file and system integrity monitoring is also helping Zoom to comply with regulatory requirements such as SOC 2 and others.

“Providing real-time file and system integrity monitoring for Zoom is critical in today’s IT environment,” said Cimcor CEO Robert E. Johnson, III. “Security and compliance practices have always been forefront for Cimcor. During this pandemic, there are new cybersecurity challenges and increased risk. We are pleased that our security and compliance software can help provide organizations with the assurance that their servers and network devices are operating in an expected and secure state.”

Alignment and integration with IT Service Management processes and products, and deployment within Zoom has also reinforced Cimcor’s strategy to support and align with SecOps industry efforts. CimTrak provides the first and only ‘in-product’ capability to create a closed-loop change management solution to reconcile expected changes with observed changes and provide automated remediating and roll-back capabilities. This capability can drive the industry averages of mean-time-to-identify (MTTI) and mean-time-to-contain (MTTC) security breaches of 206 and 73 days, respectively, down to measurements of mere minutes with CimTrak.

With 60,000-plus servers, Cimcor will work closely with Zoom to utilize its current and future releases of CimTrak to help streamline many of its security processes and compliance requirements with one solution that is cost effective, simple to install and operate.

Said Johnson, “We are excited to be a part of the fundamental shift that Zoom is creating in how we communicate both in business and in our personal lives. As they continue to expand, we also will continue to work with Zoom as a strategic partner to help provide innovative methods to secure their dynamic and rapidly growing infrastructure.”

About Cimcor, Inc.

Cimcor develops innovative, next-generation, compliance and system integrity monitoring software. The CimTrak Integrity Suite monitors and protects a wide range of physical, network, cloud, and virtual IT assets in real-time while providing detailed forensic information about all changes. CimTrak helps reduce configuration drift and ensure that systems are in a secure and hardened state. Securing your infrastructure with CimTrak helps you get compliant and stay that way. For more information, visit https://www.cimcor.com/cimtrak

Share article on social media or email:

[ad_2]

ESO Named to Inc. 5000 Fastest Growing US Companies List for Eighth Straight Year

[ad_1]

News Image

We look forward to many years of growth as we help organizations improve the health and safety of their communities.

ESO, the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, and state EMS/Trauma offices, announced today it has been named to the 2020 Inc. 5000 list of fastest-growing companies in America for the eighth straight year at 1,765. The list honors and recognizes private companies that demonstrate the highest growth over a three-year period.

“We wouldn’t be in this position without a passionate and dedicated team driven to ensure our customers succeed,” said Chris Dillie, President and CEO of ESO. “We look forward to many years of growth as we help organizations improve the health and safety of their communities.”

ESO’s growth continues in 2020 with new customers, strong customer retention and an enhanced product ecosystem for healthcare and public safety providers and responders to track data and insights, from 911 call to leaving the hospital. These efforts are particularly necessary during the COVID-19 pandemic, leading to the creation of the ESO COVID-19 Resource Center.

Not only have the companies on the 2020 Inc. 5000 been very competitive within their markets, but the list as a whole shows staggering growth compared with prior lists as well. The 2020 Inc. 5000 achieved an incredible three-year average growth of over 500 percent, and a median rate of 165 percent. The Inc. 5000’s aggregate revenue was $209 billion in 2019, accounting for over 1 million jobs over the past three years.

“The companies on this year’s Inc. 5000 come from nearly every realm of business,” says Inc. editor-in-chief Scott Omelianuk. “From health and software to media and hospitality, the 2020 list proves that no matter the sector, incredible growth is based on the foundations of tenacity and opportunism.”

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at http://www.inc.com/inc5000.

About ESO

ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data. Since its founding in 2004, the company continues to pioneer innovative, user-friendly software to meet the changing needs of today’s EMS agencies, fire departments, hospitals and state EMS offices. ESO currently serves thousands of customers throughout North America with a broad software portfolio, including the industry-leading ESO Electronic Health Record (EHR), the next generation ePCR; ESO Health Data Exchange (HDE), the first-of-its-kind healthcare interoperability platform; ESO Fire RMS, the modern fire Record Management System software platform; trauma, burn and stroke registry software; and ESO State Repository. ESO is headquartered in Austin, Texas. For more information, visit http://www.eso.com.

Share article on social media or email:

[ad_2]

Women’s Excellence Now Offers Comprehensive Treatment for Bladder Leakage

[ad_1]

News Image

Urinary leakage is very common among women, but unfortunately, many women do not receive an accurate diagnosis for their symptoms. The providers at Women’s Excellence understand that urinary leakage can have a negative impact on a woman’s lifestyle and restrict her from doing the activities she loves the most. Women’s Excellence specializes in bladder control for women and in most cases, can diagnose and develop treatment plans in less than 2 weeks.

Along with a comprehensive history and physical exam, additional testing can all be done in office to be more convenient and cost-effective for patients. Women’s Excellence will be able to create a personalized treatment plan that best suits the needs and symptoms of the patient.

“There are many factors that can impact bladder health in women”, said Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence. “Although bladder problems are common among women, bladder leakage is not normal! Our bladder specialists at Women’s Excellence utilize a comprehensive approach to your care, ensuring that each woman receives a personalized treatment plan catered to her symptom severity.”

Women’s Excellence has a variety of treatment options that include: pelvic floor physical therapy, medication, and minimally invasive out-patient procedures. Treatment options will depend on the suspected diagnosis.

If you are a woman who experiences urinary leakage, call the specialists at Women’s Excellence for an appointment today. Women’s Excellence is here to help women get their life back!

To schedule an in-office appointment or a telemedicine consultation, visit http://www.WomensExcellence.com. Online Patient Support Specialists are available Monday through Friday from 8am-5pm to assist new, current, and prospective patients. The chat is located at the bottom right corner of your computer or mobile device screen at http://www.WomensExcellence.com. During offline hours, all chats sent will be messaged directly to a Women’s Excellence team member. Offline messages will receive a response within 24 hours. Messages received during the weekend will be answered the next business week. Appointments can also be made at (248) 693-0543.

About Women’s Excellence

Women’s Excellence is the most comprehensive obstetric and gynecologic office in Michigan. Additionally, they specialize in menopause, weight control, bladder control, endometriosis, robotic surgery, oncology, and midwifery services. Women’s Excellence is committed to staying at the forefront of innovation with cutting edge technologies utilizing robotic surgery and minimally invasive surgical options when possible. The knowledgeable, compassionate physicians and healthcare providers of Women’s Excellence focus on patient-centered processes to deliver the highest quality of care. They are affiliated with most insurances. They offer seamless medical record access via a state-of-the-art patient portal and use the latest technology for record keeping and sharing, making the patient experience easier and more efficient. Women’s Excellence is taking new patients and is conveniently located throughout southeastern Michigan in Clarkston, Lake Orion, Lapeer, Rochester, Royal Oak, and West Bloomfield. Women’s Excellence is also a proud partner of Detroit’s longstanding radio network, WJR 760AM, providing expert women’s health news and information. For more information, visit http://www.WomensExcellence.com.

Share article on social media or email:

[ad_2]

Sinopsys Announces Issuance of European Patent Covering its Novel Stent for the Delivery of Dexamethasone and other Therapeutics to Key Sinus Anatomy

[ad_1]

Sinopsys Surgical logo

The issuance of this patent recognizes the novelty of the underlying technology and complements the first-generation patent filings for Sinopsys, making it a key component of our intellectual property portfolio

Sinopsys Surgical, Inc. (Sinopsys), a medical technology company focused on treatment of sinusitis and related conditions announced that the European Patent Office has granted EP Patent No. 2624876 covering Sinopsys’ implantable stent for the delivery of therapeutic agents including pharmaceuticals and saline. Previously-issued members of this patent family include US patents 9,022,967 and 9,308,358.

The Company previously received 510K clearance by the Food & Drug Administration (FDA) for use of the stent in the treatment of Epiphora (blocked tear ducts) and an Investigational Device Exemption (IDE) for the delivery of saline to the ethmoid sinuses via the stent in treatment of Chronic Sinusitis (CRS). With the stent now CE marked for the short or long-term treatment of CRS with saline, Sinopsys is planning its European product launch in H1 2021.

Sinopsys has a global patent estate covering its stent design, the implant procedure, and the use as a delivery device to the ethmoid sinus which studies have shown is a common source of infection for patients suffering from CRS.

“The issuance of this patent recognizes the novelty of the underlying technology and complements the first-generation patent filings for Sinopsys, making it a key component of our intellectual property portfolio” said Richard Babb, CEO of Sinopsys. “Our approach overcomes the challenges of accessing the ethmoid sinus through a ‘bottom up’ approach which often requires invasive, irreversible sinus surgery that, in some patients, is ineffective.”

Mr. Babb continued: “Sinopsys’ stent can be used for short or long-term treatment and easily removed by a medical professional when treatment is completed. Through clinical studies, our goal is to further expand the use of this innovative platform for other indications that may benefit from targeted saline and therapeutic delivery to the sinus anatomy.”

About Sinopsys Surgical, Inc.

Sinopsys’ stent is a sterile, single-use, long-term, surgically placed medical device composed of medical grade polydimethylsiloxane (PDMS), commonly known as silicone. The reversible, implant procedure takes under one hour without general anesthesia. The stent is designed to access the ethmoid sinus for the delivery of saline, for which it is currently approved in Europe, and for delivery of pharmaceutical therapeutics, for which additional clinical studies must be conducted. Additional information about the company can be found at http://www.sinopsyssurgical.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA (or other regulatory body) approvals, acceptance and demand for new products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, and other risks the Company may identify in the future.

Share article on social media or email:

[ad_2]

MedShift Recognized on the 2020 Inc. 5000 List of America’s Fastest Growing Private Companies

[ad_1]

“It is truly an honor to be ranked on the Inc. 5000 list, as our company has experienced wonderful success since 2016, our first full year of operation,” said MedShift CEO, Brian Phillips.

With the recent release of its version 3.0 IoT connected device platform, the addition of an in-house communications agency, and 2,222% growth throughout the last three years, MedShift announced today that it has ranked 185 on the Inc. 5000 list of the fastest growing private companies in America. Additionally, MedShift ranked as the 15th fastest growing health company in the United States.

In their first year of eligibility, 2020 marks MedShift’s first year of inclusion. “It is truly an honor to be ranked on the Inc. 5000 list, as our company has experienced wonderful success since 2016, our first full year of operation,” said MedShift CEO, Brian Phillips. Since its founding, MedShift has hired 28 Charlotte-based employees, grown revenues beyond $10,000,000 annually, and expanded its service offerings to over 160 countries worldwide.

The Inc. 5000 list displays some of America’s most innovative companies, as well as highlights the successes of each. This year’s list includes businesses that have not only been highly competitive within their respective industries, but also offered unparalleled products and services to customers with high expectations. “Our company, our people, and a dedication to offering only the best medical devices in the industry has propelled our business since inception,” said Porter Tiller, Managing Partner, MedShift. “Every day brings additional opportunity and we are very excited for what the future holds,” said Tiller.

Their in-house communications agency, MedShift Connect, has also expanded rapidly. “Our team works diligently to be sure that all clients are taken care of and provided with focused solutions to deliver positive results. Ranking amongst the top 20 fastest growing health companies in the United States is a huge accomplishment for us, as this year alone has brought with it many unexpected situations that forced our company to adapt and remain flexible,” said Victoria Olszowy, Vice President of Communications and Marketing, MedShift.

With this recognition, MedShift will receive an individual company profile on Inc.com, as well as an invitation to the annual Inc. 5000 Conference and Gala, which will be hosted virtually for the year 2020 due to COVID-19 restrictions. This week-long streaming event is currently scheduled to begin on October 19th, 2020.

“Although there are many ways to successfully rank on the Inc. 5000 list, our company met this goal through following a conservative business model, adapting to the ever-changing external environment, and remaining flexible when working with our customers,” said Phillips. “Our goals for the future include continuing to develop innovative products that are in high demand, as well as provide our customers with high-value options for placing aesthetic medical devices directly into practices within our unmatched subscription model.”

About MedShift

MedShift, founded in 2015 in Charlotte, NC delivers a platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 300 doctors in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems.

MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift’s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from nine manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers Medshift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across the manufacturer and provider spectrum and continues to empower robust integration with the leading brands and doctors in the industry.

About Inc. Media

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit http://www.inc.com.

For more information on the Inc. 5000 Conference, visit http://conference.inc.com/.

Share article on social media or email:

[ad_2]

First Certified FHIR Solution for Cures Act

[ad_1]

We are excited to offer this first of a kind plug-and-play solution to to connect providers, payers and patients and accelerate the adoption of FHIR in the healthcare community and reduce development time for EHR Vendors and Payers.

Darena Solutions today announced that BlueButtonPRO™, the company’s comprehensive patient engagement platform, has officially become the nation’s FIRST ever solution to be certified by the Office of the National Coordinator (ONC) for meeting interoperability and patient access provisions of the 21st Century Cures Act.

Earlier this year, the U.S. Department of Health and Human Services (HHS) announced two final rules, one by the Centers for Medicare & Medicaid Services (CMS) and the other by the ONC, implementing parts of the 21st Century Cures Act. These final rules established Application Programming Interface (API) requirements based on HL7® FHIR® for healthcare providers, EHR vendors and payers to support patients’ access and control of their electronic health information. ONC adopted a rich and rigorous testing tool called Inferno to ensure and verify that API vendors are following the industry standards for FHIR and complying with Cures Act requirements. The certification from Drummond Group, which is authorized by ONC to test FHIR servers using Inferno, validated BlueButtonPRO as the first FHIR based API to pass all the requirements.

BlueButtonPRO™ can be integrated with any EHR to meet the Cures Act requirements mandated by ONC for all EHR Vendors. It also meets and exceeds the CMS Interoperability and Patient Access final rule requirements for payers.

“BlueButtonPRO™ is an end-to-end FHIR solution to connect providers, payers and patients. We are excited to offer this first of a kind ‘plug-and-play’ solution to the market to accelerate the adoption of FHIR within the healthcare community and reduce development time for EHR Vendors and Payers,” said Pawan Jindal, CEO of Darena Solutions.

Darena Solution is doing a free informational live webinar on BlueButtonPRO™ to share more details. Register Here

BlueButtonPRO™ Version 2 Health IT Module is 2015 Edition Cures compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.

ABOUT DARENA SOLUTIONS

Darena Solutions delivers an ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to healthcare providers and payers. By creating channels for data sharing between providers, payers, and patients, our solutions enable healthcare organizations to achieve compliance, derive insights to make prospective decisions resulting in increased workflow efficiencies and better outcomes for patients. Visit us at http://www.darenasolutions.com. You can also connect with us on LinkedIn and Twitter.

ABOUT DRUMMOND GROUP

http://www.drummondgroup.com/

Share article on social media or email:



[ad_2]